Avalon’s New Challenges, Opportunities in Life Science Investing

March 24, 2026

 LA JOLLA – As Avalon BioVentures wraps up deploying its very first fund, the $135 million ABV1, the early stage focused venture capital firm is already lookin  

Search

RECENT PRESS RELEASES